Zanubrutinib in Chronic Lymphocytic Leukemia

Dr. Byrd reports being a scientific advisor for AstraZeneca, chair of the scientific advisory board of Newave, a major stockholder and chair of the scientific advisory board for Vincerx, a member of the scientific advisory board for Kartos Therapeutics, and a major stockholder and chair of the scientific advisory board for Eilain. Mr. Rothbaum reports being president of Quogue Capital; being a cofounder, executive chairman, and a shareholder of Acerta Pharma (acquired by AstraZeneca); being a shareholder and serving on the board of directors of Iovance; being a founder and shareholder and serving as executive chairman of Kartos Therapeutics; being a founder and shareholder and serving as executive chairman of Telios Pharma; and being named as an inventor on multiple scientific patents, including those licensed to Kartos Therapeutics and Telios Pharma. No other potential conflict of interest relevant to this letter was reported.